Figure 3.

Distribution of patients by ADAS-Cog and CIBIC-Plus response after 6 months of donepezil therapy. Patient responses on the ADAS-Cog at 6 months were categorized as improved (change from baseline ≤ -4 points), no change (-3 to 3) or worsened (≥ 4) and crossed against CIBIC-Plus improvement (ratings of 1 to 3), no change (4) or worsening (5 to 7). An asterisk (*) denotes agreement between measures – overall 45%.